RPG Life Sciences's Total Assets for the quarter that ended in Mar. 2026 was ₹7,932 Mil.
During the past 12 months, RPG Life Sciences's average Total Assets Growth Rate was 31.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 19.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 13 years, RPG Life Sciences's highest 3-Year average Total Assets Growth Rate was 19.40%. The lowest was -5.50%. And the median was 3.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
RPG Life Sciences's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
RPG Life Sciences Total Assets Related Terms
RPG Life Sciences Total Assets Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
RPG Life Sciences's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a Total Assets of ₹7,932 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on RPG Life Sciences and its competitors.
Is RPG Life Sciences' Total Assets too high?
RPG Life Sciences' current Total Assets is ₹7,932 Mil. Overall, RPG Life Sciences has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Total Assets compare to ZTS and UTHR?
RPG Life Sciences' Total Assets of ₹7,932 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on RPG Life Sciences and its competitors. RPG Life Sciences's current Total Assets is ₹7,932 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,357.90, compared to a current price of ₹2,856.90 — trading 21.2% above its estimated fair value. The current Total Assets is ₹7,932 Mil. RPG Life Sciences' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Total Assets is ₹7,932 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,856.90 is trading 21.2% above its estimated GF Value™ of ₹2,357.90.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
Total Assets: ₹7,932 Mil
GF Value™: ₹2,357.90 vs. price of ₹2,856.90 (21.2% above fair value)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
90GF Score
Get the complete analysis for NSE:RPGLIFE
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
